Keyphrases
Multiple Myeloma
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
25%
Newly Diagnosed multiple Myeloma
17%
Older Adults
16%
Myeloma
14%
Bortezomib
13%
Relapsed or Refractory multiple Myeloma
12%
Lenalidomide
12%
Overall Survival
11%
Myeloma Cells
10%
Carfilzomib
10%
Granulocyte Colony-stimulating Factor (G-CSF)
9%
Older Patients
9%
Multiple Myeloma Patients
8%
Confidence Interval
8%
Stem Cell Transplantation
8%
Myeloma Therapy
8%
Pomalidomide
7%
Multicenter Retrospective Study
7%
Mixed-methods Study
7%
Plerixafor
7%
Overall Response Rate
6%
COVID-19
6%
United States
6%
Surveillance Epidemiology
6%
Median Overall Survival
6%
Frailty
6%
Stem Cell Mobilization
6%
Comprehensive Score for Financial Toxicity
6%
Socioeconomic Status
5%
Phase I Study
5%
Progression-free Survival
5%
Racial Disparities
5%
Frailty Index
5%
Cancer Treatment
5%
CoMMpass
5%
Financial Toxicity
5%
Venous Thromboembolism
5%
Medicine and Dentistry
Multiple Myeloma
94%
Myeloma
15%
Overall Survival
15%
Malignant Neoplasm
14%
Bortezomib
12%
Lenalidomide
10%
Retrospective Study
10%
Medicare
10%
Carfilzomib
10%
Dexamethasone
7%
COVID-19
7%
Financial Toxicity
7%
Myeloma Cell
7%
Autologous Stem Cell Transplantation
6%
Socioeconomic Status
6%
Surveillance, Epidemiology, and End Results
6%
Stem Cell Transplant
5%
Stem Cell Therapy
5%
Racial Disparity
5%
Disease
5%
Frailty
5%
Comorbidity
5%